what was the first glp-1 agonist Understanding receptor agonists and their impact on drug discovery Emerging Frontiers in GLP-1 Therapeutics:

Glucagon-like peptide-1 receptor agonists, namely GLP-1 receptor agonists, are a class of drugs for the treatment of type 2 diabetes.

The global obesity treatment market is expanding at unprecedented speed, with sales of weight-loss medications forecast to rise dramatically over the next decade.

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

Now it has been shown that limited experimental data can be used to train sophisticated machine learning models to accurately predict the activity of previously uncharacterized peptide ligand variants.

The real problem seems to be retention